Showing 5151-5160 of 5961 results for "".
- Menlo Begins Enrollment for Phase 2 Studies of NK-1 for Pruritushttps://practicaldermatology.com/news/menlo-begins-enrollment-for-phase-2-studies-of-nk-1-for-pruritus/2458325/Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus associated with atopic dermatitis and for the treatment of pruritus fol
- Non-heterosexual Black Male Teens Use Tanning Beds as Much as Caucasian Female Teenshttps://practicaldermatology.com/news/non-heterosexual-black-male-teens-use-tanning-besds-as-much-as-caucasian-female-teens/2458324/The use of indoor tanning among non-heterosexual black male teens is nearly equal to that of heterosexual white females, according to a study in JAMA Dermatology. The data comes from the 2
- Skin Cancer Foundation: Bill Ridenour Is New Senior Director of Partnership Developmenthttps://practicaldermatology.com/news/skin-cancer-foundation/2458333/The Skin Cancer Foundation has appointmented Bill Ridenour to the role of senior director of partnership development. Ridenour’s career has spanned over 30 years in the advertising industry and this new position marks a switch to the nonprofit sector. Prior to his appointment, Ridenour
- National Psoriasis Foundation Awards 2016 Grants and Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-2016-grants-and-fellowships/2458334/The National Psoriasis Foundation (NPF) awarded more than $1.9 million in research funding in 2016, including 23 new projects from around the world. Established and emerging scientists received awards for their innovative work in advancing the research of p
- Provectus Biopharmaceuticals Terminates CEO and COOhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-terminates-ceo-and-coo/2458335/Provectus Biopharmaceuticals, Inc.'s Board of Directors unanimously voted to terminate Peter R. Culpepper, effective immediately, from all positions held with the company, including Chief Executive Officer and Chief Operating Officer, for cause in accordance with the terms of his employment a
- La Roche-Posay Nabs 20 Beauty Awards in 2016https://practicaldermatology.com/news/la-roche-posay-nabs-20-beauty-awards-in-2016/2458336/La Roche-Posay (LRP) won 20 beauty awards, almost doubling its wins from the previous year, the company has announced. The awards, judged by editors, industry leaders and elite experts who test thousands of beauty products before awarding top honors, bring the total skincare wins for LRP to 55 an
- Dermavant Licenses Portola Pharma's Cerdulatinib For Skin Applicationshttps://practicaldermatology.com/news/dermavant-licenses-portola-pharmas-cerdulatinib-for-skin-applications/2458338/Dermavant Sciences has licensed cerdulatinib from Portola Pharma for topical dermatologic applications. Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- Carmex Rolls Out New Comfort Care Lip Balmshttps://practicaldermatology.com/news/carmex-rolls-out-new-comfort-care-lip-balms/2458343/Harsh winter weather can wreak havoc on the lips, leaving them dry, chapped and irritated. New CARMEX COMFORT CARE™ lip balms can help, says New York City dermatologist Neil Sadick, MD at a media event. Launched in late 2016, the new line is fo
- Valeant Appoints William D. Humphries As EVP, Dermatologyhttps://practicaldermatology.com/news/valeant-appoints-william-d-humphries-as-evp-dermatology/2458348/Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to